title: Who should go first in trials with scarce agents? The views of potential participants.
authors.affiliation: Winship Cancer Institute, Emory University, Atlanta, GA, USA.
authors.forename: Rebecca D
authors.initials: RD
authors.lastname: Pentz
authors.forename: Anne L
authors.initials: AL
authors.lastname: Flamm
authors.forename: Jeremy
authors.initials: J
authors.lastname: Sugarman
authors.forename: Marlene Z
authors.initials: MZ
authors.lastname: Cohen
authors.forename: Zhiheng
authors.initials: Z
authors.lastname: Xu
authors.forename: Roy S
authors.initials: RS
authors.lastname: Herbst
authors.forename: James L
authors.initials: JL
authors.lastname: Abbruzzese
mesh_terms: D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D017277:Drug Approval; D015507:Drugs, Investigational / Q000627:therapeutic use*; D028744:Ethics Committees, Research; D005260:Female; D006297:Health Services Accessibility; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D035842:Research Subjects / Q000523:psychology*; D011795:Surveys and Questionnaires
chemical_list: D015507:Drugs, Investigational